An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry

被引:109
作者
Velazquez, EJ
Francis, GS
Armstrong, PW
Aylward, PE
Diaz, R
O'Connor, CM
White, HD
Henis, M
Rittenhouse, LM
Kilaru, R
van Gilst, W
Ertl, G
Maggioni, AP
Spac, J
Weaver, WD
Rouleau, JL
McMurray, JJV
Pfeffer, MA
Califf, RM
机构
[1] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27715 USA
[2] Duke Clin Res Inst, Durham, NC 27715 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Univ Alberta, Edmonton, AB, Canada
[5] Flinders Med Ctr, Bedford Pk, SA, Australia
[6] Estudios Cardiol, Santa Fe, Argentina
[7] Green Lane Hosp, Auckland 3, New Zealand
[8] Med Pharmaceut Consultants, Randolph, NJ USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Univ Wurzburg, Med Klin, Wurzburg, Germany
[11] ANMCO Res Ctr, Florence, Italy
[12] Fac Hosp St Anna, Brno, Czech Republic
[13] Henry Ford Hosp, Detroit, MI 48202 USA
[14] Univ Toronto, Toronto, ON, Canada
[15] Univ Glasgow, Glasgow, Lanark, Scotland
[16] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
heart failure; myocardial infarction; prognosis; left ventricular dysfunction; Killip class;
D O I
10.1016/j.ehj.2004.08.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We analysed the contemporary incidence, outcomes, and predictors of heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) before discharge in patients with acute myocardial infarction (MI). The baseline presence of HF or LVSD, or its development during hospitalisation, increases short- and long-term risk after MI, yet its incidence, predictors, and outcomes have not been well described in a large, international, general. MI population. Methods and results The VALIANT registry included 5573 consecutive MI patients at 84 hospitals in nine countries from 1999 to 2001. A multivariable logistic survival model was constructed using baseline variables to determine the adjusted mortality risk for those with in-hospital HF and/or LVSD. Baseline variables were also tested for associations with in-hospital HF and/or LVSD. Of the 5566 patients analysed, 42% had HF and/or LVSD during hospitalisation. Their in-hospital. mortality rate was 13.0% compared with 2.3% for those without HF and/or without LVSD. After adjustment for other baseline risk factors, in-hospital HF and/or LVSD carried a hazard ratio for inhospital mortality of 4.12 (95% confidence interval: 3.08-5.56). Patients with HF and/or LVSD also had disproportionately higher rates of other cardiovascular events. Conclusions HF and/or LVSD is common in the general contemporary MI population and precedes 80.3% of all in-hospital deaths after MI. Survivors of early MI-associated HF and/or LVSD have more complications, Longer hospitalisations, and are more likely to die during hospitalisation. Although baseline variables can identify MI patients at highest risk for HF and/or LVSD, such patients are less likely to receive indicated procedures and medical therapies. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1911 / 1919
页数:9
相关论文
共 41 条
[1]  
*AIRE STUD INV EFF, 1993, LANCET, V342, P8218
[2]   Clinical predictors of heart failure in patients with first acute myocardial infarction [J].
Ali, AS ;
Rybicki, BA ;
Alam, M ;
Wulbrecht, N ;
Richer-Cornish, K ;
Khaja, F ;
Sabbah, HN ;
Goldstein, S .
AMERICAN HEART JOURNAL, 1999, 138 (06) :1133-1139
[3]   Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Hoppe, U ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
de Werf, FV ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
EUROPEAN HEART JOURNAL, 2000, 21 (18) :1502-1513
[4]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[5]  
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[6]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[7]   Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the united states: Data from the National Registry of Myocardial Infarction 2 [J].
Barron, HV ;
Michaels, AD ;
Maynard, C ;
Every, NR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :360-367
[8]  
BRAUNWALD E, 2002, ACC AHA 2002 GUIDELI
[9]  
*CURE TRIAL INV, 2001, NEW ENGL J MED, V345, P1506
[10]   Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390